{
  "ticker": "LLY",
  "target_date": "2025-03-26",
  "actual_date": "2025-03-26",
  "collected_at": "2025-12-08T11:33:53.885692",
  "price": {
    "open": 840.88,
    "high": 846.56,
    "low": 821.7,
    "close": 822.0533447265625,
    "volume": 2562100,
    "change_1d_pct": -3.0,
    "change_7d_pct": 0.24,
    "change_30d_pct": -4.26
  },
  "technicals": {
    "rsi_14": 31.06,
    "sma_20": 854.0,
    "sma_50": 834.06,
    "macd": -4.924,
    "macd_signal": -2.791,
    "macd_histogram": -2.133,
    "bb_upper": 939.71,
    "bb_lower": 768.29,
    "price_vs_sma20_pct": -3.74,
    "price_vs_sma50_pct": -1.44,
    "volume_ratio": 0.71
  },
  "fundamentals": {
    "market_cap": 889129533440,
    "pe_ratio": 48.595123,
    "forward_pe": 43.769924,
    "price_to_book": 37.342865,
    "price_to_sales": 14.963523,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.81,
    "pct_from_52w_low": 59.0
  },
  "macro": {
    "spy": {
      "price": 565.35,
      "change_1d_pct": -1.19,
      "change_7d_pct": 1.65
    },
    "vix": {
      "level": 18.33,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.34
    },
    "dollar_index": {
      "level": 104.55
    },
    "gold": {
      "price": 3020.9
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Eli Lilly's GLP-1 pill could be the next key in obesity treatment",
      "source": "Yahoo",
      "datetime": 1743023071,
      "summary": "Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility. Evan Seigerman, BMO Capital Markets managing director of biopharma equity research, joins Market Dominati",
      "url": "https://finnhub.io/api/news?id=c6127959358ae451561acf9443003a60d7ba2296e97308430042bfe0a61833c1"
    },
    {
      "headline": "US is only country debating GLP-1 insurance coverage for weight loss: Cigna CEO Cordani",
      "source": "Yahoo",
      "datetime": 1743019988,
      "summary": "Cigna (CI) CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only country among developed nations where insurance coverage is being debated.",
      "url": "https://finnhub.io/api/news?id=64ce262c8731e0be72f6af4537f8d5b7c4747e2b9729830330fffd82f81d4f50"
    },
    {
      "headline": "Eli Lilly and Company (LLY): One of Two Sigma Investments\u2019 Top Stock Picks",
      "source": "Yahoo",
      "datetime": 1743014468,
      "summary": "We recently published a list of Top 10 Stocks to Buy According to Two Sigma Investments. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to Two Sigma Investments. Two Sigma Investments, LP, a New York City-based ",
      "url": "https://finnhub.io/api/news?id=389d4d1bbc060e4cd4090de283b6ea95aef837490b7c7c34a053f7dd142482cc"
    },
    {
      "headline": "Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study",
      "source": "Yahoo",
      "datetime": 1743007416,
      "summary": "Viking Therapeutics stock skidded Wednesday despite the \"encouraging\" speed with which the company enrolled patients in an obesity study.",
      "url": "https://finnhub.io/api/news?id=0d4f518ba7629572f6a60fb8e820a28959a9985ee76efc4701cb171d672ac5eb"
    },
    {
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1743006660,
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=1c762dd625d67f2dd78f4511c02b871aad98fcd82d7498511c181a50b151bb64"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742416067.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000103/xslF345X05/wk-form4_1742416067.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415936.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000101/xslF345X05/wk-form4_1742415936.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415842.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000099/xslF345X05/wk-form4_1742415842.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415665.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000097/xslF345X05/wk-form4_1742415665.xml"
    },
    {
      "form": "4",
      "date": "2025-03-19",
      "description": "xslF345X05/wk-form4_1742415462.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000095/xslF345X05/wk-form4_1742415462.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}